| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 566.303 +52.39% on 12/22/25 | | 952.000 -9.35% on 01/16/26 | +287.000 (+49.83%) since 12/19/25 |
| 3-Month | 560.000 +54.11% on 10/23/25 | | 952.000 -9.35% on 01/16/26 | +273.210 (+46.32%) since 10/17/25 |
| 52-Week | 232.500 +271.18% on 04/09/25 | | 952.000 -9.35% on 01/16/26 | +456.500 (+112.30%) since 01/17/25 |
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc...
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford...
Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB),...
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK –...
BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the successful...
Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease Negligible...
Virica Biotech Inc. , a leading developer of solutions for scaling of viral medicines, today announced it will collaborate with Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy company,...
Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer ABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12,...
The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.
Long term indicators fully support a continuation of the trend.
Relative Strength just crossed below 80%. The market has dropped from extreme overbought territory, indicating a possible trend reversal.
| 3rd Resistance Point | 991.333 |
| 2nd Resistance Point | 971.667 |
| 1st Resistance Point | 935.333 |
| Last Price | 861.000 |
| 1st Support Level | 879.333 |
| 2nd Support Level | 859.667 |
| 3rd Support Level | 823.333 |
| 52-Week High | 952.000 |
| Last Price | 861.000 |
| Fibonacci 61.8% | 677.151 |
| Fibonacci 50% | 592.250 |
| Fibonacci 38.2% | 507.349 |
| 52-Week Low | 232.500 |